my predictions: (1) random people would buy it, self-diagnose, take a regular dose, no effect, take a huge dose (2) the manufacturer would be unable to keep up with the demand of 300 million people stockpiling it
1) True. But "physician supervision" will soon be in very short supply, so the balance of risks may shift quickly. 2) This can be ameliorated with pseudoephedrine-style limits. Plus, according to Wikipedia, it's super cheap to make ($0.04/dose), so it might be quick to scale up.